Cargando…
Gene Therapy Vector Encoding Neuropeptide Y and Its Receptor Y2 for Future Treatment of Epilepsy: Preclinical Data in Rats
Gene therapy to treat pharmacoresistant temporal lobe epilepsy in humans is now being developed using an AAV vector (CG01) that encodes the combination of neuropeptide Y and its antiepileptic receptor Y2. With this in mind, the present study aimed to provide important preclinical data on the effects...
Autores principales: | Szczygieł, Julia Alicja, Danielsen, Kira Iben, Melin, Esbjörn, Rosenkranz, Søren Hofman, Pankratova, Stanislava, Ericsson, Annika, Agerman, Karin, Kokaia, Merab, Woldbye, David Paul Drucker |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746806/ https://www.ncbi.nlm.nih.gov/pubmed/33343295 http://dx.doi.org/10.3389/fnmol.2020.603409 |
Ejemplares similares
-
Disease Modification by Combinatorial Single Vector Gene Therapy: A Preclinical Translational Study in Epilepsy
por: Melin, Esbjörn, et al.
Publicado: (2019) -
Combinatorial gene therapy for epilepsy: Gene sequence positioning and AAV serotype influence expression and inhibitory effect on seizures
por: Melin, Esbjörn, et al.
Publicado: (2023) -
Inhibition of epileptiform activity by neuropeptide Y in brain tissue from drug-resistant temporal lobe epilepsy patients
por: Wickham, Jenny, et al.
Publicado: (2019) -
Editorial: Gene Therapy in the CNS – Progress and Prospects for Novel Therapies
por: Ledri, Marco, et al.
Publicado: (2021) -
Neuropeptide y and neuropeptide s in major depressive disorder and post-traumatic stress disorder: Preclinical andclinical studies
por: Mathe, A.
Publicado: (2021)